WHAT IS CLAIMED IS:

1. A multivalent pneumococcal conjugate composition, comprising 22-27 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B, and wherein the protein carrier comprises CRM_{197} and tetanus toxoid.

2. The multivalent pneumococcal conjugate composition of claim 1, comprising 27 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 23A, 23B, 22F, 23F, 24F, 33F, and 35B.

3. The multivalent pneumococcal conjugate composition of claim 1, comprising 26 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, and 35B and four serotypes selected from 15A, 15C, 23A, 23B, and 24F.

4. The multivalent pneumococcal conjugate composition of claim 1, comprising 25 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, and 35B and three serotypes selected from 15A, 15C, 23A, 23B, and 24F.

5. The multivalent pneumococcal conjugate composition of claim 1, comprising 24 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, and 35B and two serotypes selected from 15A, 15C, 23A, 23B, and 24F.

6. The multivalent pneumococcal conjugate composition of claim 1, comprising 23 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, and 35B and one serotype selected from 15A, 15C, 23A, 23B, and 24F.

7. The multivalent pneumococcal conjugate composition of claim 1, comprising 22 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, and 35B.

8. The multivalent pneumococcal conjugate composition of any one of claims 1-7, wherein at least two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM_{197}, wherein the at least two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, 5, 15B, and 22F.

9. The multivalent pneumococcal conjugate composition of claim 8, wherein the at least two capsular polysaccharides that are conjugated to tetanus toxoid are serotypes 15B and 22F.

10. The multivalent pneumococcal conjugate composition of claim 2, wherein the capsular polysaccharides from serotypes 1 and 5 are conjugated to the tetanus toxoid, and the capsular

polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B are conjugated to CRM_{197}.

11. The multivalent pneumococcal conjugate composition of claim 2, wherein the capsular polysaccharides from serotypes 1 and 3 are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B are conjugated to CRM_{197}.

12. The multivalent pneumococcal conjugate composition of claim 2, wherein the capsular polysaccharides from serotypes 3 and 5 are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 1, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, and 35B are conjugated to CRM_{197}.

13. The multivalent pneumococcal conjugate composition of claim 2, wherein the capsular polysaccharides from serotypes 1, 5, 15B, and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15C, 18C, 19A, 19F, 23A, 23B, 23F, 24F, 33F, and 35B are conjugated to CRM_{197}.

14. The multivalent pneumococcal conjugate composition of claim 2, wherein the capsular polysaccharides from serotypes 1, 3, 15B, and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15C, 18C, 19A, 19F, 23A, 23B, 23F, 24F, 33F, and 35B are conjugated to CRM_{197}.

15. The multivalent pneumococcal conjugate composition of claim 2, wherein the capsular polysaccharides from serotypes 3, 5, 15B, and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 1, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15C, 18C, 19A, 19F, 23A, 23B, 23F, 24F, 33F, and 35B are conjugated to CRM_{197}.

16. A multivalent pneumococcal conjugate composition, comprising 27 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14,

15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, 35B, and one of *Streptococcus pneumoniae* serotypes 2, 12A, 16F, 17F, 20A, 20B, 20F, 31, 45, and 46.

17. The multivalent pneumococcal conjugate composition of claim 16, wherein the protein carrier comprises CRM_{197} and tetanus toxoid.

18. The multivalent pneumococcal conjugate composition of claim 16 or 17, wherein four of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM_{197}.

19. The multivalent pneumococcal conjugate composition of claim 18, wherein the four capsular polysaccharides that are conjugated to tetanus toxoid are serotypes 15B, 22F and two serotypes selected from the group consisting of serotypes 1, 3, and 5.

20. The multivalent pneumococcal conjugate composition of any one of claims 1-19, further comprising an adjuvant.

21. The multivalent pneumococcal conjugate composition of claim 20, wherein the adjuvant is an aluminum-based adjuvant.

22. The multivalent pneumococcal conjugate composition of claim 21, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide.

23. The multivalent pneumococcal conjugate composition of claim 22, wherein the adjuvant is aluminum phosphate.

24. A vaccine comprising the multivalent pneumococcal conjugate composition of any one of claims 1-23 and a pharmaceutically acceptable excipient.

25. The multivalent pneumococcal conjugate composition of any one of claims 1-23 or the vaccine of claim 24 for use in the prophylaxis of *Streptococcus pneumoniae* infection or disease in a subject.

26. The composition or the vaccine for use of claim 25, wherein the subject is a human who is at least 50 years old and the disease is pneumonia or invasive pneumococcal disease (IPD).

27. The composition or the vaccine for use of claim 25, wherein the subject is a human who is at least 6 weeks old and the disease is pneumonia, invasive pneumococcal disease (IPD), or acute otitis media (AOM).

28. The composition or the vaccine for use of claim 27, wherein the subject is 6 weeks to 5 years of age, 2 to 15 months of age, or 6 to 17 years of age.

29. The composition or the vaccine for use of claim 25, wherein the subject is a human.

30. The composition or the vaccine for use of any one of claims 25-29, wherein the multivalent pneumococcal conjugate composition or the vaccine is to be administered by intramuscular injection.

31. The composition or the vaccine for use of any one of claims 25-30, wherein the multivalent pneumococcal conjugate composition or the vaccine is to be administered as part of an immunization series.